Short discussion by Sam S. Chang on QUILT-3.032 cohort A data
What are the implications of these findings for clinical practice?
This educational activity has been funded and sponsored by Accord Healthcare, and is intended for health care professionals (HCPs) only. The views are those of the speaker(s).
The product mentioned may not be registered in all countries. Prescribing information may vary per country. HCPs must refer to their country prescribing information.
ANKTIVA (nogapendekin alfa inbakicept-pmln) UK prescribing information can be found here
ANKTIVA (nogapendekin alfa inbakicept-pmln) EU prescribing information can be found here
ANKTIVA (nogapendekin alfa inbakicept-pmln) UK SmPC with legal classification can be found here
ANKTIVA (nogapendekin alfa inbakicept-pmln) EU SmPC with legal classification can be found here
ANKTIVA EU indication: ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
Adverse events should be reported. Reporting forms, and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to ImmunityBio at 1-877-ANKTIVA (1-877-265-8482).
This educational activity has been funded and sponsored by
and focusses on
